Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (10879)	7/22/1999 10:01:00 PM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

Funny how you link up events and price of stock when to me it is just price catching up to propwash of spin. George, in my opinion the analysts will spin their way through FDA tight reign on approvals with no problem at all. If one Biotech gets stuck in the approval process there is always another Biotech to spin into. Example, where did all that money spin to when it left Iomega? Is not the approval process the same as someone failing to execute a hitech business plan? Hmmmm, I think I hear some sizzle surrounding Application Service Provider stocks, now how are these any different in making a choice of which to invest in versus trying to guess what drugs will get approval in Biotech investing? My point is if the money is there, spin will rule every time. At least in the short term AND you know how I hate making money in short periods of time. Only my opinions.